CAS 610798-31-7

Icotinib

Description:

Icotinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of non-small cell lung cancer (NSCLC). It specifically targets the epidermal growth factor receptor (EGFR), which is often mutated in various cancers, leading to uncontrolled cell proliferation. The compound is characterized by its ability to selectively inhibit the activity of EGFR, thereby blocking downstream signaling pathways that promote tumor growth and survival. Icotinib is administered orally and has been shown to have a favorable pharmacokinetic profile, allowing for effective systemic exposure. Its chemical structure includes a quinazoline core, which is common among EGFR inhibitors, and it exhibits good solubility in various solvents. The drug's efficacy and safety profile have been evaluated in clinical trials, demonstrating its potential as a therapeutic option for patients with EGFR-mutant NSCLC. As with other targeted therapies, monitoring for adverse effects and resistance mutations is essential in clinical practice.

Formula: C₂₂H₂₁N₃O₄

InChI: InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)

InChI key: InChIKey=QQLKULDARVNMAL-UHFFFAOYSA-N

SMILES: N(C=1C2=C(C=C3C(=C2)OCCOCCOCCO3)N=CN1)C4=CC(C#C)=CC=C4

Synonyms:

• Bpi 2009H
• Icotinib int. N-1
• N-(3-Ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine
• [1,4,7,10]Tetraoxacyclododecino[2,3-g]quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-
• Icotinib

Icotinib

CAS: 610798-31-7

Icotinib

Purity: ≥98%

Molecular weight: 391.42g/mol

Ref: 54-BUP04458

Icotinib

CAS: 610798-31-7

Icotinib (Conmana) is an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity.

Formula: C₂₂H₂₁N₃O₄

Purity: 99.76% - 99.94%

Color and Shape: Solid

Molecular weight: 391.42

Ref: TM-T6153